Ohcanbohtosat - Pasi A. Jänne

Aiddostahte ozu
  1. 1
    Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer

    Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer Dahkki Luca Toschi, Pasi A. Jänne

    Almmustuhtton 2008
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Inhibitors that activate

    Inhibitors that activate Dahkki Karen Cichowski, Pasi A. Jänne

    Almmustuhtton 2010
    Viečča ollesdeavstta Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    New Strategies for Treatment of <i>ALK</i>-Rearranged Non–Small Cell Lung Cancers

    New Strategies for Treatment of <i>ALK</i>-Rearranged Non–Small Cell Lung Cancers Dahkki Takaaki Sasaki, Pasi A. Jänne

    Almmustuhtton 2011
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Epidermal Growth Factor Receptor Mutations in Patients with Non–Small Cell Lung Cancer

    Epidermal Growth Factor Receptor Mutations in Patients with Non–Small Cell Lung Cancer Dahkki Bruce E. Johnson, Pasi A. Jänne

    Almmustuhtton 2005
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas

    Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas Dahkki Alexis B. Cortot, Pasi A. Jänne

    Almmustuhtton 2014
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    The quest to overcome resistance to EGFR-targeted therapies in cancer

    The quest to overcome resistance to EGFR-targeted therapies in cancer Dahkki Curtis R. Chong, Pasi A. Jänne

    Almmustuhtton 2013
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine

    Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine Dahkki Amanda J. Redig, Pasi A. Jänne

    Almmustuhtton 2015
    Viečča ollesdeavstta Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Circumventing Cancer Drug Resistance in the Era of Personalized Medicine

    Circumventing Cancer Drug Resistance in the Era of Personalized Medicine Dahkki Levi A. Garraway, Pasi A. Jänne

    Almmustuhtton 2012
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

    Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Dahkki Jeffrey A. Engelman, Pasi A. Jänne

    Almmustuhtton 2008
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

    Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor... Dahkki Pasi A. Jänne, Bruce E. Johnson

    Almmustuhtton 2006
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

    Thirty Years of HER3: From Basic Biology to Therapeutic Interventions Dahkki Heidi M. Haikala, Pasi A. Jänne

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

    Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Dahkki Peter S. Hammerman, Pasi A. Jänne, Bruce E. Johnson

    Almmustuhtton 2009
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Discovery of selective irreversible inhibitors for EGFR-T790M

    Discovery of selective irreversible inhibitors for EGFR-T790M Dahkki Wenjun Zhou, Dalia Ercan, Pasi A. Jänne, Nathanael S. Gray

    Almmustuhtton 2010
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    New Targetable Oncogenes in Non–Small-Cell Lung Cancer

    New Targetable Oncogenes in Non–Small-Cell Lung Cancer Dahkki Geoffrey R. Oxnard, Adam F. Binder, Pasi A. Jänne

    Almmustuhtton 2013
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Kinase drug discovery 20 years after imatinib: progress and future directions

    Kinase drug discovery 20 years after imatinib: progress and future directions Dahkki Philip Cohen, Darren A.E. Cross, Pasi A. Jänne

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    Targeting<i>MET</i>Dysregulation in Cancer

    Targeting<i>MET</i>Dysregulation in Cancer Dahkki Gonzalo Recondo, Jianwei Che, Pasi A. Jänne, Mark M. Awad

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    Responsiveness to Cetuximab without Mutations in<i>EGFR</i>

    Responsiveness to Cetuximab without Mutations in<i>EGFR</i> Dahkki Zenta Tsuchihashi, Shirin Khambata‐Ford, Nasser H. Hanna, Pasi A. Jänne

    Almmustuhtton 2005
    Viečča ollesdeavstta Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

    Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer Dahkki Ken Takezawa, Isamu Okamoto, Kazuto Nishio, Pasi A. Jänne, Kazuhiko Nakagawa

    Almmustuhtton 2011
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    The biology and treatment of EML4-ALK non-small cell lung cancer

    The biology and treatment of EML4-ALK non-small cell lung cancer Dahkki Takaaki Sasaki, Scott J. Rodig, Lucian R. Chirieac, Pasi A. Jänne

    Almmustuhtton 2010
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    Lung cancer in patients who have never smoked — an emerging disease

    Lung cancer in patients who have never smoked — an emerging disease Dahkki Jaclyn LoPiccolo, Alexander Gusev, David C. Christiani, Pasi A. Jänne

    Almmustuhtton 2024
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: